{
    "id": 184,
    "name": "bone cancer",
    "source": "DOID",
    "definition": "A connective tissue cancer that is located_in bone and is characterized by uncontrolled cellular proliferation that destroys normal bone tissue. [url:http\\://www.cancer.gov/cancertopics/factsheet/Sites-Types/bone, url:http\\://www.cancer.gov/cancertopics/types/bone, url:http\\://www.wrongdiagnosis.com/b/bone_cancer/intro.htm]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        "3348"
    ],
    "termId": "DOID:184",
    "evidence": [
        {
            "id": 11090,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Keytruda (pembrolizumab) treatment resulted in an overall response rate of 5% (2/40) and 12-week progression free rate of 28% (11/40) in patients with bone sarcoma (J Clin Oncol 35, 2017 (suppl; abstr 11008)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 184,
                "name": "bone cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9070,
                    "pubMedId": null,
                    "title": "Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARC028 and biomarker analyses.",
                    "url": "http://meetinglibrary.asco.org/record/145286/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT02574728",
            "title": "Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3143,
                    "therapyName": "Celecoxib + Cyclophosphamide + Etoposide + Sirolimus",
                    "synonyms": null
                }
            ]
        }
    ]
}